BC Extra | Dec 12, 2019
Financial News

Momenta, Forty Seven, Assembly push 2019 follow-on tally to $21.5B

Momenta, Forty Seven and Assembly joined the year-end push for follow-on stock offerings, raising an aggregate of $520 million. The financings bring this year’s tally for follow-ons to about $21.5 billion, well short of 2018’s...
BC Extra | Dec 12, 2019
Financial News

Trio of follow-ons lift 2019 tally of deals

December’s rush of follow-ons has continued with Rocket, Constellation and Marinus all pricing follow-on offerings since Tuesday’s close to raise more than $340 million. But cash raised via follow-ons continues to lag behind last year's...
BC Week In Review | Dec 15, 2017
Clinical News

CHMP requests more information on betrixaban VTE MAA

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said EMA’s CHMP requested additional information related to its MAA for betrixaban (PRT054021) for extended-duration prophylaxis of venous thromboembolism (VTE) in adults with acute medical illness and risk factors for VTE....
BC Week In Review | Jul 5, 2017
Clinical News

FDA approves Portola's Bevyxxa betrixaban to prevent VTE

FDA approved an NDA from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) for Bevyxxa betrixaban (PRT054021) to prevent venous thromboembolism (VTE) in hospitalized and post-discharge adults with acute illnesses who are at high risk for complications. The oral...
BC Extra | Jun 23, 2017
Company News

Portola soars after FDA approves anticoagulant Bevyxxa

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) jumped $17.81 (47%) to $56.06 on Friday after FDA approved Bevyxxa betrixaban to prevent venous thromboembolism (VTE) in hospitalized and post-discharge adults with acute illnesses who are at high risk for...
BioCentury | Apr 7, 2017
Finance

To market, to market

Investors are hoping that a slew of approvals and data readouts can maintain biotech’s momentum on the heels of several high-profile successes that came just before or after 1Q’s end. Chief among those was Vertex...
BC Week In Review | Feb 9, 2017
Clinical News

Betrixaban regulatory update

Portola said FDA does not plan to hold an advisory committee meeting to discuss an NDA for the company's betrixaban. The agency did not identify any issues during its mid-cycle review that require a meeting,...
BC Extra | Feb 8, 2017
Company News

Portola: FDA won't require betrixaban meeting

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) said FDA does not plan to hold an advisory committee meeting to discuss an NDA for the company's betrixaban ( PRT054021 ). The agency did not identify any issues during its mid-cycle...
BC Week In Review | Jan 4, 2017
Clinical News

Betrixaban regulatory update

FDA accepted and granted Priority Review to an NDA for betrixaban as extended-duration prophylaxis of venous thromboembolism (VTE) in acute medically ill patients with risk factors for VTE. The PDUFA date is June 24. Portola...
BC Extra | Dec 23, 2016
Company News

Portola jumps on Priority Review for betrixaban

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) gained $6.33 (34%) to $25.06 after it said FDA accepted and granted Priority Review to the biotech’s NDA for betrixaban ( PRT054021 ) for extended-duration prophylaxis of venous thromboembolism (VTE) in acute medically...
Items per page:
1 - 10 of 395